Why the study?
Proliferative diabetic retinopathy involves increased new vessel formation driven by angiogenic factors such as ANGPT2, prompting the design of targeted siRNA to decrease retinal neovascularization.
Does siRNA targeting ANGPT2 reduce retinal neovascularization in a rat model of diabetic retinopathy?
Does siRNA targeting ANGPT2 reduce retinal neovascularization in a rat model of diabetic retinopathy?
Intravitreal administration of siRNA targeting ANGPT2 reduces retinal neovascularization in a diabetic rat model, suggesting a potential therapeutic approach for proliferative diabetic retinopathy.
Hypothesis-generating for ANGPT2 siRNA in diabetic retinopathy; human trials required before any clinical consideration.
Diabetes is a disease that leads to proliferative diabetic retinopathy (PDR), which is associated with an increase of new vessels formation due to an overexpression of angiogenic factors, such as angiopoietin 2 (ANGPT2). The aim of this work was to design a siRNA targeting ANGPT2 to decrease the retinal neovascularization associated with PDR. Adult male Wistar rats weighing 325–375 g were used. Diabetes was induced by a single dose of streptozotocin (STZ, 60 mg/kg i.p.). The siRNAs were designed, synthesised, and administered intravitreally at the beginning of diabetes induction (t0), and after 4 weeks of diabetes evolution (t4), subsequently evaluated the retinal neovascularization (junctions and lacunarity) and ANGPT2 expression in the retina by RT-PCR, after 4 weeks of the siRNAs administration. The results showed that the administration of STZ produced significant increases in blood glucose levels, retinal neovascularization (augmented junctions and lower lacunarity), and ANGPT2 expression, while the administration of the ANGPT2-siRNAs at different groups (t0 and t4) reduces the junctions and increases the lacunarity in diabetic rats. Therefore, we conclude that the administration of siRNAs targeting ANGPT2 could be an option to decrease the retinal neovascularization associated with PDR and halt the progression of blindness caused by diabetes.
No takes yet. Share an insight, caveat, or question.
Cabrera‐Becerra et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: